Q32 Bio (QTTB) announced that the company has dosed the first patients in both the Part A open-label extension and Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with alopecia areata. The trial is intended to support advancement into pivotal trials upon completion, pending review of the results. Q32 Bio expects to report topline data from SIGNAL-AA Part B in the first half of 2026.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTTB: